149 related articles for article (PubMed ID: 6320170)
21. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
22. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus.
Rooney C; Howe JG; Speck SH; Miller G
J Virol; 1989 Apr; 63(4):1531-9. PubMed ID: 2538644
[TBL] [Abstract][Full Text] [Related]
23. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
Fresen KO; Hausen H
Int J Cancer; 1976 Feb; 17(2):161-6. PubMed ID: 175026
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-induced increase in the concanavalin-A receptor density of established EBV-negative lymphoma lines in vitro.
Siegert W; Mönch T; Valet G
Exp Hematol; 1980 Nov; 8(10):1173-82. PubMed ID: 6262102
[TBL] [Abstract][Full Text] [Related]
25. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
Klein G; Ehlin-Henriksson B; Schlossman SF
J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
[TBL] [Abstract][Full Text] [Related]
26. Post-transcriptional mechanisms of deregulation of MYC following conversion of a human B cell line by Epstein-Barr virus.
Lacy J; Summers WP; Summers WC
EMBO J; 1989 Jul; 8(7):1973-80. PubMed ID: 2551670
[TBL] [Abstract][Full Text] [Related]
27. Hexose transport in Epstein-Barr virus (EBV) negative lymphoma lines and their EBV converted, virus genome carrying sublines.
Siegert W; Mönch T
Blut; 1981 Nov; 43(5):297-305. PubMed ID: 6275931
[TBL] [Abstract][Full Text] [Related]
28. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
29. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
30. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.
Trivedi P; Spinsanti P; Cuomo L; Volpe M; Takada K; Frati L; Faggioni A
J Virol; 2001 May; 75(10):4929-35. PubMed ID: 11312367
[TBL] [Abstract][Full Text] [Related]
31. Expression of the BLA antigen, defined by the monoclonal 38.13 antibody, on Burkitt lymphoma lines, lymphoblastoid cell lines, their hybrids and other B-cell lymphomas and leukemias.
Klein G; Manneborg-Sandlund A; Ehlin-Henriksson B; Godal T; Wiels J; Tursz T
Int J Cancer; 1983 May; 31(5):535-42. PubMed ID: 6303966
[TBL] [Abstract][Full Text] [Related]
32. Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis.
Sculley TB; Walker PJ; Moss DJ; Pope JH
J Virol; 1984 Oct; 52(1):88-93. PubMed ID: 6090712
[TBL] [Abstract][Full Text] [Related]
33. Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines.
Klein G; Zeuthen J; Terasaki P; Billing R; Honig R; Jondal M; Westman A; Clements G
Int J Cancer; 1976 Nov; 18(5):639-52. PubMed ID: 62724
[TBL] [Abstract][Full Text] [Related]
34. Diploid human lymphoblastoid and Burkitt lymphoma cell lines: susceptibility to murine NK cells and heterotransplantation to nude mice.
McCormick KH; Giovanella BC; Klein G; Nilsson K; Stehlin JS
Int J Cancer; 1981 Oct; 28(4):455-8. PubMed ID: 6273332
[TBL] [Abstract][Full Text] [Related]
35. Retrovirus-like particles in EBV-negative Burkitt's lymphoma cell line but not in EBV-DNA-positive lines from patients with ataxia telangiectasia and Down's syndrome.
Kotler M; Balabanova H; Friedmann A; Becker Y
Br J Cancer; 1979 Apr; 39(4):414-21. PubMed ID: 220999
[TBL] [Abstract][Full Text] [Related]
36. Integrated viral DNA sequences in Epstein-Barr virus-converted human lymphoma lines.
Andersson-Anvret M; Lindahl T
J Virol; 1978 Mar; 25(3):710-8. PubMed ID: 205668
[TBL] [Abstract][Full Text] [Related]
37. Differential cytotoxicity of tumour promoter TPA for EBV-negative human lymphoma cell lines and their EBV-converted sublines.
Béchet JM; Guétard D
Int J Cancer; 1983 Jul; 32(1):61-5. PubMed ID: 6305854
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers.
Torsteinsdottir S; Masucci MG; Lenoir G; Klein G; Klein E
Cell Immunol; 1984 Jul; 86(2):278-86. PubMed ID: 6329520
[TBL] [Abstract][Full Text] [Related]
39. Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis.
Kaptein JS; Lin CK; Wang CL; Nguyen TT; Kalunta CI; Park E; Chen FS; Lad PM
J Biol Chem; 1996 Aug; 271(31):18875-84. PubMed ID: 8702548
[TBL] [Abstract][Full Text] [Related]
40. Comparison between growth characteristics of an Epstein--Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro.
Steinitz M; Klein G
Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3518-20. PubMed ID: 171663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
